Cargando...
Contemporary agents in the management of metastatic castration-resistant prostate cancer
Docetaxel-based chemotherapy has been the standard of care for metastatic castration-resistant prostate cancer (mCRPC) since 2004. Over the past few years, there has been a significant paradigm shift in the treatment landscape of this disease. A deeper understanding of prostate cancer biology, along...
Guardado en:
| Publicado en: | Can Urol Assoc J |
|---|---|
| Autores principales: | , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Canadian Medical Association
2016
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5167603/ https://ncbi.nlm.nih.gov/pubmed/28096932 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5489/cuaj.4112 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|